Back to Search

MYGN

Myriad Genetics Inc
Data: 2026-10-23
$5.82
Price
1.04%
Change
$8.50
52W High
$2.74
52W Low
Full AI Analysis Buy/Sell Forecast Trendline Why Moving Charts Options
Analyzing positioning… Options positioning — based on yesterday's biggest open-interest changes See the chart Institutional flows
Track record
signal day → next-day price move
Quick Stats
Oct 23, 2026

39.4

AI Score

EXTENDED

0.72

Volume Ratio

Nov 04, 2026

Next Earnings

19

+ve Days (30d)

10

-ve Days (30d)

MYGN Price vs Max Options Open Interest

How to read this: the line is the stock price; the bars show where the most option open interest sits each day. Strikes with heavy open interest often act as magnets or barriers for price ("max pain" zones). Scroll right for the most recent days.

MYGN Max Change In Options Open Interest

How to read this: each bar is the option contract whose open interest changed the most yesterday. Green bars = new positions being opened (conviction building at that strike); red bars = positions being closed. Call builds above the current price suggest upside bets; put builds below it suggest hedging or downside bets.

MYGN Options - Sort by Max open Interest (near term)

23rd October 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI		 Volume Ask PC Delta Vega Volatility % change Track

MYGN Daily Out of Money Options - Sort by Max open Interest (near term)

23rd October 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI		 Volume Ask PC Delta Vega Volatility % change Track

MYGN Daily In the Money Options - Sort by Max open Interest (near term)

23rd October 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI		 Volume Ask PC Delta Vega Volatility % change Track

MYGN Most Active Options by Volume(near term)

23rd October 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike Volume OI Change in
OI		 Ask PC Delta Vega Volatility % change Track
MYGN Technical Chart Pro Chart
  • Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
  • SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
  • Options OI: Shows max open interest strikes. High OI = significant price levels.
  • Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
  • Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
  • Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
  • Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
  • Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select an indicator above — it will be added as a pane under the price chart with aligned dates.

Volume Profile Analysis

Horizontal histogram showing volume distribution at each price level with buying/selling pressure

MYGN Stock Summary

Last updated Oct 23, 2026

MYGN is currently trading at $5.82, positioned above its 200-day moving average of $4.61, indicating a long-term uptrend. The stock has a 52-week range of $2.74 to $8.5.

Technical Analysis: The 50-day moving average stands at $3.88, which is below the current price, signaling bullish near-term momentum. The RSI (Relative Strength Index) reads 74.413, suggesting the stock is in overbought territory (bullish but caution advised).

Money Flow Indicators: The Chaikin Money Flow (20-day) is -0.033, which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates MYGN at 39.4/100 with a EXTENDED recommendation.

MYGN (Myriad Genetics Inc) Indicators

Last updated Oct 23, 2026

Indicator Value
RSI(14) 74.413
CMF (20) -0.033
ROC (10) 35.035
ADX (14) 41.495
Indicator Value
MACD (12,26,9) 0.4
AROONOSC (14) 7.143
WILLAMS %R (14) -6.5
MFI (14) 84.236

MYGN Candlestick Patterns

Validated patterns fired in the last 10 sessions. Hit rate = how often price moved in the signal's direction within 5 trading days (backtest: 2.7M signals, 3,500 liquid stocks, Feb 2025–Sep 2026). Baseline: a random stock closes higher 5 days later 53% of the time. Click a row to see the candle on the chart.

Date Pattern Signal 5-Day Hit Rate Edge vs Baseline Sample
Oct 16 Marubozu (bearish) (contrarian — textbook says the opposite) Bullish 56.2% +3.2 pts 30540
Oct 13 Three Inside Down (contrarian — textbook says the opposite) Bullish 56.9% +3.9 pts 8868

These are statistical tilts, not standalone trade setups. Only patterns with a measured edge are shown — roughly 50 of 60 textbook patterns showed no edge and are hidden.

Myriad Genetics Inc is above both the 50 Day and 200 Day SMA which is considered Bullish.

MYGN Moving Averages Analysis

Myriad Genetics Inc has been above 50 day sma 1 times in last 30 days. Last time it was above 50 day sma was on Oct 23, 2026

Myriad Genetics Inc has been above 200 day sma 1 times in last 30 days. Last time it was above 200 day sma was on Oct 23, 2026

MYGN (Myriad Genetics Inc) Simple Moving Averages

Moving Averages are last updated Oct 23, 2026

Days MA
10 4.77
20 4.53
30 4.35
50 3.88
100 4.39
200 4.61

MYGN Fundamental Analysis

P/E (Forward) 54.0541
P/E (Trailing) --
Market Cap ($) 550.9 million
Earnings/Share ($) -1.22
Net Profit Margin (%) -0.1396
Dividend/Share ($) --
EPS Estimate Current Year ($) -0.7391
EPS Estimate Next Year ($) -0.5887
WallStreet Target Price ($) 4.49
Most Recent Quarter

Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.